EUCTR2011-000084-27-DE进行中（未招募）不适用
DOUBLE BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY OF BF2.649 COMPARED TO PLACEBO IN ADD-ON TO SODIUM OXYBATEIN THE TREATMENT OF NARCOLEPTIC PATIENTS WITH RESIDUAL EXCESSIVE DAYTIME SLEEPINESS (EDS) DURING 8 WEEKS. - HARMONY IV
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Bioprojet
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Males or females, aged 18 years old and over.
- •Patients with a diagnosis of narcolepsy according to the International Classification of Sleep Disorders (ICSD-2) criteria
- •Patients treated with sodium oxybate (Xyrem®) with a stable dosage for at least 2 months prior to the trial.
- •Patients complaining of residual EDS with an ESS score >= 12
- •Patients should be free of non authorized drugs or discontinue any psychostimulant medication at least 3 weeks before randomisation (V2).
- •Females of child-bearing potential must use a medically accepted effective method of birth control, agree to continue this method for the duration of the study and be negative to serum pregnancy test performed at the screening visit. Females should not be breast-feeding patient.
- •In the opinion of the investigator, the patient must have adequate support to comply with the entire study requirements as described in the protocol (e.g. transportation to and from trial site, self rating scales, drug compliance, scheduled visits, etc).
- •Patient must have voluntarily expressed a willingness to participate in this study, signed and dated an informed consent prior to beginning this protocol required procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Psychiatric and neurological disorders, other than narcolepsy/cataplexy, such as moderate or severe psychosis or dementia, bipolar illness, severe anxiety, clinical severe depression (BDI = 16) with suicidal risk (item G BDI > 0), or depression treated for less than 8 weeks, history of seizure disorder or other problem that in the investigator’s opinion would preclude the patient’s participation and completion of this trial or comprise reliable representation of subjective symptoms.
- •Patients working in an occupation requiring variable shift work or routine night shifts.
- •Patients with an untreated sleep apnea disorder (defined as an apnea index > 10/h or an apnea/hypopnea index>15/h) or who have any other cause of daytime sleepiness.
- •Use of hypnotics, tranquilizers, sedating antihistamines, psychostimulants for the treatment of EDS (amphetamine and amphetamine-like CNS stimulants, modafinil, methylphenidate or others), benzodiazepines, anticonvulsants or clonidine will not be accepted at least 3 weeks before randomization (V2) and during study.
- •Current or recent (within one year) history of a substance abuse or dependence disorder including alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
- •Other active clinically significant illness, including unstable cardiovascular, or neoplasic pathology which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise the study participation.
- •Patient with a known history of long QTc syndrome (e.g. syncope or arythmia) or presenting any significant serious abnormality of the ECG (e.g. recent myocardial infarction), or QTc interval strictly higher than 450 ms (electrocardiogram Bazett’s corrected QT interval (QT x/? [HR/60]).
- •Patients with Severe Hepatic Impairment or with Severe Renal Impairment, or with any other significant abnormality in the physical examination or clinical laboratory results.
- •Known hypersensitivity to the tested treatment including active substance and excipients.
- •Patients participating in an other study and the use of any investigational therapy within the 30 days prior to the entry in this study.
- •Patient without any medical care insurance
研究者
相似试验
进行中（未招募）
不适用
DOUBLE BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY OF BF2.649 COMPARED TO PLACEBO IN ADD-ON TO SODIUM OXYBATE IN THE TREATMENT OF NARCOLEPTIC PATIENTS WITH RESIDUAL EXCESSIVE DAYTIME SLEEPINESS (EDS) DURING 8 WEEKS.arcolepsyMedDRA version: 14.1Level: LLTClassification code 10048322Term: Narcolepsy aggravatedSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10028713Term: NarcolepsySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10007737Term: CataplexySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10048323Term: Cataplexy aggravatedSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 15.0Level: LLTClassification code 10028715Term: Narcolepsy with cataplexySystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-000084-27-ESBioprojet60
进行中（未招募）
不适用
STUDY TO ASSESS THE EFFICACY OF BF2.649 IN THE TREATMENT OF NARCOLEPTIC PATIENTS WITH RESIDUAL EXCESSIVE DAYTIME SLEEPINESS.EUCTR2011-000084-27-FIBioprojet50
已完成
不适用
RANDOMIZED DOUBLE-BLIND STUDY ON THE EFFICACY AND SAFETY OF BMS - 207147 IN RELATION TO FLUCONAZOLE IN THE TREATMENT OF IMMUNOCOMPROMISED PATIENTS WITH ESOPHAGEAL CANDIDIASISPER-019-00BRISTOL MYERS SQUIBB PERU S.A.,
进行中（未招募）
不适用
Examination of effictiveness of iron containing infusion in preventing anemia after heart surgery in childreEUCTR2014-002107-16-ATGeneral Hospital Linz
招募中
不适用
A comparison between two regimes for Labour induction in Intrauterine fetal deathCTRI/2014/03/004489RS MEDICAL COLLEGE KOLKATA100